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Abstract
The aryl hydrocarbon receptor (AHR) mediates many toxic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). However, 
the AHR alone does not explain the widely different outcomes among organisms. To identify the other factors involved, 
we evaluated three transgenic mouse lines, each expressing a different rat AHR isoform (rWT, DEL, and INS) providing 
widely different resistance to TCDD toxicity, as well as C57BL/6 and DBA/2 mice which exhibit a ~ tenfold divergence in 
TCDD sensitivity (exposures of 5-1000 μg/kg TCDD). We supplement these with whole-genome sequencing, together with 
transcriptomic and proteomic analyses of the corresponding rat models, Long–Evans (L–E) and Han/Wistar (H/W) rats 
(having a ~ 1000-fold difference in their TCDD sensitivities; 100 μg/kg TCDD), to identify genes associated with TCDD-
response phenotypes. Overall, we identified up to 50% of genes with altered mRNA abundance following TCDD exposure are 
associated with a single AHR isoform (33.8%, 11.7%, 5.2% and 0.3% of 3076 genes altered unique to rWT, DEL, C57BL/6 
and INS respectively following 1000 μg/kg TCDD). Hepatic Pxdc1 was significantly repressed in all three TCDD-sensitive 
animal models (C57BL/6 and rWT mice, and L–E rat) after TCDD exposure. Three genes, including Cxxc5, Sugp1 and 
Hgfac, demonstrated different AHRE-1 (full) motif occurrences within their promoter regions between rat strains, as well 
as different patterns of mRNA abundance. Several hepatic proteins showed parallel up- or downward alterations with their 
RNAs, with three genes (SNRK, IGTP and IMPA2) showing consistent, strain-dependent changes. These data show the 
value of integrating genomic, transcriptomic and proteomic evidence across multi-species models in toxicologic studies.
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Introduction
TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) is a mem-
ber of the dioxin class of environmental pollutants. It is 
a persistent, highly lipophilic compound that can be cre-
ated as a by-product during production of some herbicides 
and through the incineration of chlorine-containing com-
pounds (Von Burg 1988). TCDD toxicity impacts almost 
all organ systems in mammals, with effects ranging from 
chloracne (particularly in humans) to immunosuppres-
sion, wasting syndrome, hepatotoxicity and acute lethal-
ity (Kransler et al. 2007). There are large differences in 
the lethality of TCDD, both between and within a given 
species. Two rodent species, hamster and guinea pig, show 
roughly 5000-fold difference in sensitivity to TCDD toxic-
ity, with  LD50 values of 1157–5051 μg/kg and 0.6–2 μg/
kg, respectively (Kransler et al. 2007). The DBA/2 mouse 
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strain exhibits a ~ tenfold lower TCDD responsiveness 
compared with the C57BL/6 strain to a wide variety of 
biochemical and toxic impacts of TCDD (reviewed in 
Pohjanvirta 2011). For example, the  LD50 values for male 
DBA/2 and C57BL/6 mice are 2570 and 180–305 μg/
kg respectively (Chapman and Schiller 1985; Pohjan-
virta et al. 2012). Perhaps the most dramatic example of 
intraspecies differences in TCDD-susceptibility exists 
between the TCDD-resistant Han/Wistar (Kuopio; H/W) 
rat, which has an  LD50 of > 9600 μg/kg TCDD and the 
TCDD-sensitive Long–Evans (Turku/AB; L–E) rat, whose 
 LD50 values are 9.8 μg/kg for females and 17.7 μg/kg for 
males (Pohjanvirta et al. 1993).
Structural features of the aryl hydrocarbon receptor 
(AHR) play a major role in the diversity of TCDD-induced 
toxicities across species and strains. The AHR is a ligand-
dependent transcription factor in the PER-ARNT-SIM (PAS) 
superfamily, which is evolutionarily conserved across fish, 
birds and mammals (Hahn et al. 1997). Normally bound 
to chaperone proteins including hsp90 and XAP2 in the 
cytosol, AHR can be activated by binding of ligands to the 
PAS-B domain, leading to nuclear localization (Rowlands 
and Gustafsson 1997). Once in the nucleus and free of 
chaperone proteins, AHR dimerizes with the AHR Nuclear 
Translocator (ARNT) protein and binds to AHR response 
elements (AHREs) in the genome, altering transcription of 
specific target genes (Shen and Whitlock 1992). The AHR 
also has other, ‘non-genomic’ actions (reviewed in Mat-
sumura 2009). For example, ligand activation of the AHR 
leads to increased intracellular  Ca2+, kinase activation and 
induction of Cox-2 transcription to promote a rapid inflam-
matory response (Dong et al. 2010).
Evidence for involvement of the AHR in TCDD toxicity 
comes from numerous studies, including species with struc-
tural AHR variants and Ahr knockout models. Mice lacking 
the Ahr gene are phenotypically (Fernandez-Salguero et al. 
1996; Schmidt et al. 1996; Mimura et al. 1997) and bio-
chemically (Tijet et al. 2006; Boutros et al. 2009) unrespon-
sive to TCDD, as are Ahr-knockout rats (Harrill et al. 2016). 
Additionally, differences in the structure of the AHR protein 
result in a wide range of susceptibilities to dioxin toxicity. 
For example, the H/W rat is TCDD-resistant primarily due 
to a point mutation in the transactivation domain of the Ahr 
gene. This creates a cryptic splice site, leading to two dis-
tinct protein products [termed the deletion (DEL) and inser-
tion (INS) isoforms] which are shorter than the wild type rat 
AHR (present in the L–E strain) (Pohjanvirta et al. 1998). 
Of these, expression of the INS isoform is predominant; 
however both are expressed in a number of tissues (Moffat 
et al. 2007). Numerous studies have sought to exploit these 
genetic differences among strains and species to decipher 
the mechanisms of dioxin toxicity (Boverhof et al. 2006; 
Boutros et al. 2008, 2011; Yao et al. 2012).
The AHR is not the only mediator of dioxin toxicities: 
evaluation of rat lines generated through breeding of H/W 
and L–E rats suggests involvement of a second gene (termed 
gene “B”) in the extreme resistance of H/W rats to TCDD-
induced toxicities (Pohjanvirta 1990; Tuomisto et al. 1999). 
Line A (Ln-A) rats contain the H/W Ahr and demonstrate 
similar resistance to TCDD-induced lethality as H/W rats; 
however, they appear to harbour the wild type (L–E) form of 
an as-yet unidentified gene “B” that is proposed to contribute 
to the phenotypic response to TCDD. Alternatively, Line B 
(Ln-B) rats express the wild type Ahr along with the H/W 
form of gene “B”, and demonstrate an intermediate  LD50 of 
830 µg/kg TCDD. Finally, Line C (Ln-C) rats do not fall far 
from L–E rats in sensitivity to TCDD  (LD50 20–40 µg/kg), 
and express wild type forms of both the Ahr and gene “B” 
(Tuomisto et al. 1999). It is thus unclear which responses are 
due solely to the various AHR and gene “B” isoforms and 
which are artifacts of the genetic heterogeneity at non-AHR 
loci among species and strains.
To isolate the molecular and phenotypic effects of dif-
ferent AHR genetic variants, we exploit a transgenic mouse 
model, termed “AHR-ratonized mice”, in which the endog-
enous AHR of C57BL/6 mice is ablated and either the rat 
wild-type (rWT), the DEL or INS variant is inserted into the 
mouse genome (Pohjanvirta 2009), as well as the TCDD-
resistant DBA/2 mouse strain. The DEL isoform confers 
only moderate resistance to TCDD toxicity, relative to 
the INS isoform (Pohjanvirta 2009). We compare hepatic 
transcriptomic responses of these transgenic mice to one 
another and to their corresponding TCDD-sensitive and 
resistant strains/lines of rat. Results are then supplemented 
with whole-genome sequencing (WGS) of L–E and H/W 
rats to further isolate the specific genes responsible (i.e. 
gene “B”) for differential toxicities and to further character-
ize the mechanism by which TCDD activation of the AHR 
causes toxicity. Finally, the hepatic responses of these two 
rat strains to TCDD are contrasted by a proteomics approach. 
These combined proteomic, transcriptomic and genomic 
resources provide novel, complementary data on the sig-
nificance of AHR structural properties as determinants of 
TCDD sensitivity and on candidate target genes for TCDD 
toxicity which can be utilized also in future studies.
Results
Experimental design
Our experimental strategy is outlined in Fig. 1 and Sup-
plementary Table 1. We examined TCDD-mediated tran-
scriptional changes associated with various AHR isoforms 
within animals that have different backgrounds (Experiment 
#1, EXP1) or identical genetic backgrounds (Experiment #2, 
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EXP2). Here we focus on liver as it shows large phenotypic 
differences between TCDD-resistant and TCDD-sensitive 
animals following exposure. Moreover, liver exhibits high 
expression of AHR (Pohjanvirta 2009), thereby making it 
an appropriate model for determining the effects of AHR 
isoforms on responses to TCDD. For EXP1, C57BL/6 and 
DBA/2 mice, along with rWT mice, were treated with a sin-
gle dose of 0, 5 or 500 µg/kg TCDD in corn oil vehicle, 
with tissue collected 19 h after. For EXP2, AHR-ratonized 
(INS/DEL/rWT) and C57BL/6 mice were treated with a sin-
gle dose of 0, 125, 250, 500 or 1000 µg/kg TCDD in corn 
oil vehicle. These doses were selected so as to discriminate 
among the various strains/lines with regard to their overt 
toxicity responses. The approximate  LD50 value for male 
C57BL/6 mice in our laboratory is 305 µg/kg (Pohjanvirta 
et al. 2012), while male DBA/2 mice are reported to have a 
 LD50 of 2570 µg/kg TCDD (Chapman and Schiller 1985). 
In the case of male rWT, DEL and INS mice, the dose of 
500 µg/kg was lethal to 4/6, 2/6 and 0/6 animals respectively 
(Pohjanvirta 2009). Thus, 5 µg/kg was definitely, and 125 µg/
kg probably, sub-lethal to all animals in the present study, 
whereas the other doses would have been variably fatal over 
time. The first time point (19 h) should reveal early (and 
thus most primary) changes in gene expression levels, while 
Fig. 1  This study evaluated 
hepatic transcriptomic profiles 
of 80 male mice that carry vari-
ant AHR isoforms (ratonized 
mice)—C57BL/6, rWT, DEL 
and INS—and treated with 
doses of 0, 125, 250, 500, or 
1000 μg/kg TCDD in corn oil 
vehicle. Livers were excised at 
4 days post-exposure and RNA 
abundance was profiled using 
microarrays. An additional 
36 male mice (n = 12 each 
C57BL/6, rWT and DBA/2 
(Ala375Val)) were treated 
with doses of 0, 5, or 500 μg/
kg TCDD in corn oil vehicle 
and liver tissue collected 19 h 
post-exposure. Data from two 
earlier studies that analyzed 
two strains of rats, Han/Wistar 
(H/W—INS and DEL) and 
Long–Evans (rWT), at various 
times post-treatment were 
included in the analysis, after 
filtering for orthologous genes 
using HomoloGene. Differen-
tially abundant genes were sub-
jected to pathway analysis using 
GOMiner, transcription factor 
binding site (TFBS) analysis 
and overlap visualization of 
significantly altered genes. 
Sequencing of genomic DNA 
isolated from liver of untreated 
L–E and H/W rats (n = 2 each) 
was performed and processed 
as shown. SNVs were identified 
and used to detect novel and/
or lost TFBS within each rat 
strain. Genes containing such 
sites were further examined for 
changes to mRNA abundance 
using the above mentioned 
microarray data
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the second (4 days) is the time when histological alterations 
in the liver are first discernible in rats (Pohjanvirta et al. 
1989). Hepatic tissue was collected 4 days following expo-
sure and transcriptional profiling performed. Arrays were 
pre-processed independently for each group (Supplementary 
Figures 1–3). Transcriptomic data from 85 animals across 
4 rat strains/lines were used for comparison (Boutros et al. 
2011; Yao et al. 2012). Genes which demonstrated altered 
mRNA abundance as well as pathways showing significant 
enrichment for these genes only in the TCDD-sensitive 
(C57BL/6, rWT, L–E) or only in TCDD-resistant cohorts 
(INS, H/W) were identified. Finally for EXP3, WGS was 
performed on hepatic tissue gDNA extracted from untreated 
H/W and L–E rats. An average coverage of 85× and 15× was 
achieved for H/W and L–E respectively (Table 1). Single 
nucleotide variants (SNVs) were annotated with predicted 
impact and compared between rat strains (see “Materials and 
methods”). These datasets were further supplemented with 
proteomic measurements from H/W rat liver following treat-
ment with 100 µg/kg TCDD or corn oil for 4 days as well 
as L–E rat liver following treatment with 100 µg/kg TCDD, 
corn oil vehicle or feed-restriction (Linden et al. 2014), also 
for 4 days (n = 5 animals per group). 
Transcriptomic responses to TCDD
TCDD treatment triggered changes in hepatic mRNA abun-
dance in each of the mouse cohorts studied, but with sub-
stantial differences in the magnitude, direction and identity 
of genes affected. Animals treated with corn oil vehicle 
alone displayed similar transcriptomic profiles regardless of 
AHR isoform [adjusted Rand index (ARI) = 0.69 for TCDD, 
control] whereas TCDD-treated animals cluster more closely 
to animals with the same AHR isoform, regardless of dose 
(Supplementary Figure 4a, b). Following linear modeling, 
a p value sensitivity analysis was performed to compare dif-
ferent significance thresholds (Supplementary Figure 4c–i). 
For downstream analyses, a dual threshold of effect-size 
 (log2|fold change| > 1) and significance (padj < 0.05) was used 
to define transcripts with a statistically significantly differ-
ence in abundance following TCDD treatment.
Early transcriptomic responses to TCDD differ by Ahr 
genotype
Previous studies observed transcriptomic changes as early 
as 6 h in C57BL/6 mouse liver (Prokopec et al. 2015) and 
19 h in rat liver (Boutros et al. 2008; Moffat et al. 2010; 
Yao et al. 2012) following exposure to TCDD. To further 
study the role that the Ahr has in ‘early onset’ changes, we 
identified genes with significant differential mRNA abun-
dance following a dose of 5 or 500 µg/kg TCDD in sensi-
tive mouse strains (C57BL/6 or rWT) or resistant (DBA/2) 
mouse strains. We observed clear trends in response, with 
the higher dose resulting in an increased number of dif-
ferentially abundant transcripts; this difference between 
the two doses was especially pronounced in DBA/2 mice 
in which only a handful of transcripts changed at 5 µg/kg 
TCDD (Fig. 2a). The absolute number of changes in tran-
script abundance was further considerably different among 
the groups at each dose tested. Intriguingly, liver from the 
ratonized rWT mouse demonstrated a heightened response 
relative to both the C57BL/6 and DBA/2 mice, even at 5 µg/
kg TCDD. This could suggest differences in binding affinity 
for either TCDD and/or AHREs of the rWT Ahr relative to 
the mouse Ahr. As assessed by a modified sucrose gradient 
assay and Woolf plot, the apparent binding affinity of AHR 
for TCDD is quite similar in C57BL/6 mice and L–E rats 
harboring the WT receptor (Kd 1.8 vs. 2.2 nM respectively), 
while it is notably lower (16 nM) in the DBA/2 mouse strain 
(Okey et al. 1989; Pohjanvirta et al. 1999). However, after 
a lethal dose of TCDD, rWT mice tend to die much more 
rapidly compared with C57BL/6 mice (Pohjanvirta 2009), 
which probably bears on the difference in transcript abun-
dance. In further support of this, at 500 µg/kg TCDD a 
similar number of differentially abundant transcripts was 
detected in C57BL/6 and DBA/2 mice, but in rWT mice 
the number was twice as high. We examined the overlap of 
genes amongst these three groups (Fig. 2b) and identified 34 
genes with differential mRNA abundance in all three groups. 
Five of these are part of the ‘AHR-core’ gene battery—a 
set of 11 well-documented TCDD-responsive genes with 
transcription previously shown to be mediated by the AHR 
Table 1  Summary of L–E and H/W rat sequencing. Genomic DNA from hepatic tissue of H/W and L–E rats was sequenced using the AB 
SOLiD platform
Reads were aligned to the reference (rn6) using BFAST, followed by variant calling using GATK’s HaplotypeCaller. Variants were filtered to 
obtain only novel and unique high-quality variants for each strain, followed by annotation using SnpEff. Final numbers indicate total number of 
unique [H/W or L–E only, after removal of known variants (Atanur et al. 2013)], homozygous, high impact variants
Strain Average coverage Number of 
Variants (pre-
filter)
Number of Vari-
ants (post-filter)
Number of 
homozygous 
SNVs
Number of 
homozygous 
Indels
Number of “High 
Impact” Variants
Number of unique 
“High Impact” Vari-
ants
H/W 85.34 3235191 1138926 176578 127870 756 35 SNVs, 608 indels
L–E 14.73 2004271 1187745 161620 19520 220 116 SNVs, 14 indels
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(Nebert et al. 1993; Yeager et al. 2009; Deb and Bandiera 
2010; Watson et al. 2014) (Fig. 2c). An additional four of 
these genes had differential RNA abundance in at least two 
groups: Cyp1a2 in C57BL/6 and DBA/2 (borderline signifi-
cant  (log2 fold change = 0.99) in rWT) and Fmo3, Nqo1 and 
Ugt1a9 only in the TCDD-sensitive cohorts. Inmt shows sig-
nificant repression in only rWT at this early time point, while 
Aldh3a1 shows no response in mice [consistent with previ-
ous studies (Lee et al. 2015; Prokopec et al. 2015, 2017)]. 
We next examined sets of genes which demonstrated altered 
RNA abundance in the TCDD-resistant DBA/2 mouse 
liver or TCDD-sensitive cohorts (Fig. 2d–e). Genes with 
altered mRNA abundance in DBA/2 mice included Apol7c, 
Tnfaip8l3 and Htatip2 (both low and high dose exposure). 
These genes were similarly altered in the sensitive strains. 
Rpl18a and Mbd6 had altered mRNA abundance exclusively 
in the resistant group (high and low dose), while two addi-
tional genes, Onecut2 and Lipg had altered mRNA abun-
dance exclusively in the resistant mouse, high dose group 
(Fig. 2d). Alternatively, Fig. 2e highlights differentially 
abundant transcripts that appear exclusively in sensitive 
animals, regardless of dose (including Acpp, Dclk3, Fmo2, 
Pmm1 and Ugdh) and genes that respond in only sensitive 
strains but at a higher dose (such as Acot2, Acot3 and Smcp). 
Pathway analysis suggested that genes with altered RNA 
abundance in DBA/2 mice are involved in lipase activity, 
while the sensitive strains both demonstrate an enrichment 
of genes involved in xenobiotic and flavonoid metabolic pro-
cesses as well as myristoyl- and palmitoyl-CoA hydrolase 
and oxidoreductase activities.
Late transcriptomic responses to TCDD in ratonized mice
We next sought to identify changes in transcriptomic pat-
terns that occur late following exposure to TCDD. Four 
days after exposure to TCDD, a considerable difference in 
the hepatic transcriptomic profiles of H/W and L–E rats has 
been observed (Boutros et al. 2011). Therefore, we evalu-
ated the responses of ratonized transgenic mice at this same 
time point and utilizing a dose–response experiment. As 
above, we identified a large number of genes with differen-
tial mRNA abundance in the TCDD-sensitive rWT mouse, 
as well as the more resistant DEL mouse, and a muted 
response in highly resistant INS mouse (Fig. 3a). As a clear 
dose–response regarding number of differentially abundant 
RNAs was not apparent, we focused downstream analyses 
to the 500 µg/kg TCDD group, for consistency with EXP1. 
As explained above, this dose is above the  LD50 for the 
TCDD-sensitive mice (C57BL/6 and rWT) but below it in 
TCDD-resistant cohorts [DEL and INS; (Pohjanvirta 2009)]. 
Fig. 2  Differential transcrip-
tomic profiles emerge early 
following exposure to TCDD. a 
Using a dual threshold of |log2 
fold change| > 1, padj < 0.05, 
genes with differential mRNA 
abundance were identified. As 
expected, the TCDD-resistant 
DBA/2 mouse liver showed 
a transcriptional response 
following only the high dose 
of TCDD, while the sensitive 
C57BL/6 and rWT strains dem-
onstrated considerable changes 
following low exposure that 
increased with dose. b Overlap 
of these genes in each cohort, 
following exposure to 500 μg/
kg TCDD for 19 h.  Log2 fold 
change of c “AHR-core” genes, 
d genes with significantly 
altered mRNA abundance 
in resistant mouse liver or 
e sensitive strains. Dot size 
indicates magnitude of change 
following exposure to TCDD 
relative to controls, while colour 
indicates direction of change 
(orange = increased abundance, 
blue = decreased abundance); 
background shading indicates 
FDR-adjusted p value
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Interestingly, the largest overlap occurred between the DEL 
and rWT isoforms, consistent across all doses (Fig. 3b, 
Supplementary Figure 5b–d) and consistent with a previ-
ous study demonstrating reduced protection against TCDD 
toxicity by this DEL isoform in these models (Pohjanvirta 
2009). A total of 15 genes were identified in all four groups, 
including six of the eleven “AHR-core” genes (Fig. 3c). As 
expected, responses to TCDD of Cyp1a1 and Cyp1b1 were 
consistent across all AHR isoforms and all doses (Pohjan-
virta 2009). Similarly, Ahrr, Nqo1, Tiparp and Ugt1a9 
showed consistent changes at the 500 µg/kg TCDD dose 
across all strains. Interestingly, Inmt did not show changes 
to mRNA abundance in the C57BL/6 or INS but did show 
dramatic repression in the DEL and rWT, indicating a 
response specific to these AHR-genotypes. Exclusive to 
the TCDD-sensitive cohorts, 28 genes were identified with 
altered transcriptomic response to TCDD, with only three 
genes exclusive to the TCDD-resistant cohorts. Interest-
ingly, this included Fmo2 (Fig. 3d, right panel) which was 
altered exclusively in the TCDD-sensitive cohorts at the 
early time point used in EXP1 (Fig. 3d, left panel) suggest-
ing a short-lived induction in sensitive strains/lines that is 
delayed in resistant ones. It is noteworthy, though, that the 
same resistant models were not used in both time-points, and 
thus Fmo2 induction may have had a decreasing trend also 
in DEL and INS mice over time.
Differences between rat and mouse hepatic response 
to TCDD
We next expanded the study by contrasting our findings 
with a rat-transcriptomic dataset previously generated under 
similar experimental conditions (Moffat et al. 2010; Boutros 
et al. 2011; Yao et al. 2012). We evaluated 11,932 orthol-
ogous genes, obtained from EXP1 and EXP2 (500 μg/kg 
TCDD), L–E and H/W rats (1/4/10 days, 100 μg/kg TCDD) 
and Ln-A and Ln-C rats (19 h, 100 μg/kg TCDD). Using 
the same dual threshold of |log2 fold change| > 1, padj < 0.05, 
there was little overlap between species (with a higher 
degree of overlap amongst different strains/lines of the same 
species independent of TCDD response phenotype; Fig. 4). 
Thus, in the transgenic mice, the host species was a more 
important determinant of the resultant responsiveness than 
the AHR isoform. Four ‘AHR-core’ genes showed altered 
mRNA abundance in all cohorts (Cyp1a1, Cyp1b1, Nqo1 
and Tiparp). Nfe2l2 showed altered transcript abundance in 
Fig. 3  Late transcriptomic changes in AHR ratonized mouse liver. 
a Using a dual threshold of |log2 fold change| > 1, padj < 0.05, genes 
with differential mRNA abundance were identified for each AHR 
isoform. A clear dose–response pattern was not observed; however, 
a considerable increase in the number of genes demonstrating altered 
mRNA abundance was detected among the highly TCDD-resistant 
INS isoform, TCDD-sensitive rWT and C57BL/6 isoforms, and 
moderately TCDD-resistant DEL isoform. b Overlap of these genes 
in each cohort, following exposure to 500  μg/kg TCDD for 96  h. c 
 Log2 fold change of “AHR-core” genes ordered by AHR isoform and 
increasing exposure. Dot size indicates magnitude of change follow-
ing exposure to TCDD relative to controls  (log2 fold change), while 
colour indicates direction of change (orange = increased abundance, 
blue = decreased abundance); background shading indicates FDR-
adjusted p value. d Fmo2 demonstrated significant changes in mRNA 
abundance earlier among TCDD-sensitive strains that appear later in 
TCDD-resistant ones. Bar height shows magnitude of change  (log2 
fold change); *p < 0.05, **p < 0.01, ***p < 0.001
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all cohorts except INS from EXP2 and Inmt was repressed 
more consistently in rats (H/W and L–E liver at 19 h, 4 
and 10 days, and Ln-A and Ln-C at 19 h) than mice (near 
significant in rWT at 19 h, DEL/rWT at 4 days, all doses).
Of the 28 genes identified above in the sensitive cohorts 
(EXP2), 18 had homologs present in the rat dataset. Of these, 
Igfbp3 demonstrated differential mRNA abundance (|log2 fold 
change| > 1, padj < 0.05) in both the TCDD-sensitive L–E rats 
and TCDD-resistant H/W rats following a 4-day exposure 
while Pxdc1 was altered only in L–E rat liver and Cyp1a2 
was altered only in H/W rat liver (though this showed near sig-
nificant induction in all animals tested). PX domain-containing 
protein 1 (Pxdc1) is significantly repressed in TCDD-sensi-
tive cohorts (4 days following exposure, regardless of dose 
in C57BL/6, rWT, as well as in L–E rats; near significant in 
DEL mice). This gene is poorly characterized and differential 
Fig. 4  Comparison of transcriptomic changes between species and 
AHR isoform. Intersection of the number of genes with significantly 
altered mRNA abundance (|log2 fold change| > 1, padj < 0.05) in 
each examined cohort. Responses following treatment with 500  μg/
kg (mouse strains) or 100 μg/kg (rat strains, blue text) TCDD for a 
19 h or b 4 days. Only orthologous genes were examined. c Pcp4l1 
demonstrated significant changes in mRNA abundance among most 
cohorts. Bar height shows magnitude of change  (log2 fold change, all 
with increased abundance relative to controls); *p < 0.05, **p < 0.01, 
***p < 0.001. d Pathway analysis of significantly differentially abun-
dant orthologous genes in mouse and rat cohorts was performed using 
GoMiner. Significantly enriched biological pathways (padj ≤ 0.01, 
enrichment > 15) were identified within each group and status is 
shown across all groups. Dot size indicates enrichment score while 
background shading represents significance level. Empty cells indi-
cate 0 genes within that pathway were differentially abundant
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transcript abundance could not be directly attributed to the 
AHR because this gene demonstrated variable presence of 
Transcription Factor Binding Sites (TFBSs) among the species 
and strains/lines used (Supplementary Table 2). Additionally, 
no genomic differences were detected between the TCDD-
sensitive L–E and TCDD-resistant H/W rats (Supplementary 
Table 3), suggesting that Pxdc1 is a poor candidate for the 
proposed gene “B”.
Pcp4l1 demonstrated induced RNA abundance in most 
cohorts (Fig. 4c, top). Genomic analyses indicated the pres-
ence of multiple AHRE-1 (core, extended) and ARE motifs 
within the promoter region of this gene in both species; 
however, with more occurrences in mice (n = 8 AHRE-1 
(core) and 2 ARE motifs) than rats (n = 7 AHRE-1 (core) 
and 1 ARE motifs). Pcp4l1 encodes Purkinje cell protein 
4-like 1 and is typically expressed in neuronal tissue; it has 
been hypothesized to be a calmodulin inhibitor (Morgan and 
Morgan 2012). Interestingly, this gene is adjacent to and in 
the reverse orientation of, Nr1i3—a gene encoding a tran-
scription factor previously associated with enhanced TCDD 
sensitivity (Prokopec et al. 2015), showing higher mRNA 
abundance in TCDD-sensitive male mice than TCDD-
resistant female mice. Nr1i3 demonstrates altered transcrip-
tional response following TCDD exposure across species 
(Fig. 4c, bottom): hepatic mRNA abundance was increased 
after TCDD exposure in C57BL/6 mice (4 days, all doses) 
and earlier in rWT mice and L–E rats (19 h). This response 
was followed by a significantly reduced mRNA abundance 
in rWT mice (4 days) and L–E rats (4 and 10 days). This 
gene also shows different presence of AHREs in its pro-
moter region between species (n = 2 AHRE-1 (core) motif in 
both mice and rats; 4 ARE motifs in mice; 1 AHRE-2 and 1 
ARE motif in rats). No differences in AHREs were observed 
between H/W and L–E rats for either Pcp4l1 or Nr1i3. This 
makes these genes interesting candidates for involvement in 
TCDD-induced toxicity.
Finally, functional pathways affected by TCDD were 
compared across these datasets, using only orthologous 
genes (Supplementary Table 4). Unsurprisingly, sensitive 
strains exhibit a larger number of significantly enriched path-
ways than do resistant animals, and many of these pathways 
are altered in multiple strains/lines (Fig. 4d). Specifically, 
TCDD-sensitive animals display a more significant enrich-
ment of altered transcripts among metabolic and oxidoreduc-
tase activity pathways than resistant animals whereas resist-
ant animals exhibit responses mostly in metabolism-related 
processes and transport activities.
Identifying candidates for gene “B” using genomic 
variants
The H/W rat strain has astonishing resistance to TCDD tox-
icities, predominantly conferred by a point mutation in the 
transactivation domain of the Ahr gene (Pohjanvirta et al. 
1998). Part of this resistance has also been contributed to 
a second hypothesized gene, termed gene “B” (Tuomisto 
et al. 1999). Of the 642 nuclear “high impact” homozygous 
variants unique to the H/W strain (Supplementary Table 3), 
209 mapped to genes evaluated in our microarray cohorts. 
Twenty of these did not show altered transcript abundance 
in any of our cohorts. Five genes demonstrated altered 
mRNA abundance exclusively in H/W rat (Supplementary 
Fig. 6), and 125 showed TCDD-mediated mRNA abundance 
changes in at least one experimental group, excluding H/W 
rat liver (28 of these showed significantly altered mRNA 
abundance in at least 8 non-H/W groups). None of these 
gene-sets contained more variant genes with altered mRNA 
abundance than expected by chance alone (hypergeometric 
test, p > 0.05). Additionally, a single “high impact” homozy-
gous mitochondrial SNP was identified in H/W that results 
in a lost stop codon in mitochondrial gene NADH dehydro-
genase 6 (MT-nd6). This was not found in other rat strains.
Since the above list does not include variants located 
within intergenic regions, an alternative analysis was per-
formed to identify genes demonstrating altered transcript 
abundance associated with modified regulatory regions. 
Specifically, we searched the H/W genome for novel or lost 
transcription factor binding sites (TFBSs) specific to the 
AHR with the hypothesis that a gain of a TFBS may allow 
AHR-mediated transcription of a TCDD-resistance gene 
whereas a loss of a TFBS would prevent transcription of a 
TCDD-susceptibility gene. In total, 13.4% of genes (1446 
of 10,772 with available TFBS data) had either a gain or 
loss of at least one of the AHREs examined (Supplemen-
tary Table 2). Of these, 32 exhibited changes to the number 
of AHRE-1 (full) motifs within their promoter regions as 
compared to the TCDD-sensitive L–E rat (Table 2), with 17 
showing a gain and 15 a loss. Perhaps more interestingly, 
15 genes harboured this motif in H/W (with none identified 
in the same region for L–E), while nine genes demonstrated 
a complete loss of this motif from the promoter region in 
H/W rats. TCDD-responsive genes were not enriched in 
those demonstrating a novel AHRE-1 (full) motif in H/W 
and TCDD-responsiveness in H/W liver (hypergeometric 
test; Supplementary Table 5).
We next evaluated differential transcriptional patterns 
for genes demonstrating differences among these TFBSs 
between H/W and L–E rats. For example, Cxxc5 shows a 
loss of the AHRE1 (full) motif within its promoter region 
in H/W (one found in H/W and two in L–E/rn6) and exhib-
its significantly reduced transcript abundance in liver from 
both L–E (4 and 10 days) and the TCDD-sensitive Ln-C rat 
(19 h) following exposure to TCDD (Table 2). Similarly, 
Sugp1 demonstrated a complete loss of this motif from the 
H/W strain relative to L–E (n = 0 and 1 respectively), with 
mice (mm9) similarly lacking the AHRE-1 (full) motif. 
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This gene shows significantly increased mRNA abundance 
in only the TCDD-sensitive L–E rat liver (4 day,  log2 fold 
change = 0.33, padj = 0.0012). Alternatively, Hgfac demon-
strates a novel AHRE-1 (full) motif in the H/W rat (n = 1 in 
H/W and 0 in L–E/rn6) and its’ mRNA abundance is sig-
nificantly increased in both strains, 4 and 10 days following 
treatment, but is much higher in L–E rat liver (Table 2). No 
changes were detected in the AHR-ratonized mice, and this 
gene was not included on the arrays used for 1 day expo-
sures, preventing assessment in the Ln-A and Ln-C rats. This 
list supplies a robust set of 12 gene “B” candidates, in par-
ticular Cxxc5, with evidence of altered TFBSs and altered 
transcriptional patterns in only rats that may prove suitable 
for further mechanistic investigation.
Table 2  Genes demonstrating 
altered transcription factor 
binding sites in rats
The number of occurrences for the AHRE-I (full) motif within a ± 3 kbp region around the transcription 
start site for each gene was determined for each H/W and L–E rat. Genes which demonstrate either a gain 
or loss of this motif in H/W relative to L–E may represent gene “B”. Of the 11,392 rat/mouse orthologous 
genes examined, 32 were revealed to have either a gain or loss of this motif in H/W rats. Of these, 19 
showed altered mRNA abundance following treatment with TCDD in at least one rat strain at one or more 
time points evaluated. *significantly altered mRNA abundance in TCDD treated group relative to con-
trols (padj < 0.05). Column labeled ‘Other’ indicates significantly altered mRNA abundance in: a = Ln-A; 
c = Ln-C (100 μg/kg TCDD, padj < 0.05); m = C57BL/6 mouse; d = DEL, i = INS, r = rWT AHR-ratonized 
mice (500 μg/kg TCDD, padj < 0.05)
Gene symbols highlighted with bold font indicate key gene “B” candidates (n = 12)
Gene ID Symbol AHRE-I 
(full) counts
H/W Coefficient L–E Coefficient Other
H/W L–E 1 day 4 day 10 day 1 day 4 day 10 day
300089 Pmm1 3 2 0.58* 0.76* 0.98* 0.82* 1.65* 2.26* mdrac
338475 Nrep 2 3 – 2.27* – 1.69* – 1.81* – 1.21 – 3.13* – 2.89* drac
83589 Apba1 2 3 – 0.07 – 0.01 0.09 – 0.03 0.03 – 0.03
170582 Fgf19 2 1 0.06 – 0.06 – 0.01 – 0.06 0.03 – 0.09 d
100529260 Ankhd1 1 2 0.26 0.09 – 0.02 0.19 – 0.05 – 0.04
291,670 Cxxc5 1 2 0.11 0.01 0.04 – 0.16 – 0.31* – 1.00* c
313878 Galnt14 1 2 NA 0.02 0.16 NA 0.02 – 0.21
54264 Mafb 1 2 0.29 – 0.71 – 0.66* – 0.49 – 1.08* – 1.47*
114214 Dffa 1 0 0.04 0.09 0.02 0.04 0.05 – 0.01
116565 Lrpap1 1 0 0.08 0.10 0.44* 0.20 0.52* 0.65* d
192215 Slc9a5 1 0 – 0.12 0.01 – 0.05 0.07 – 0.07 – 0.28*
29146 Jag1 1 0 – 0.07 – 0.22 – 0.07 – 0.02 – 0.20 – 0.09
291964 Fhod1 1 0 NA 0.08 – 0.03 NA – 0.15 0.12
294287 Phf1 1 0 0.06 0.09 – 0.08 0.03 – 0.20 – 0.17 dr
307350 Afg3l2 1 0 0.11 – 0.08 – 0.03 0.14 0.00 0.41*
362456 Arhgdib 1 0 – 0.08 0.01 0.05 0.09 0.45* 0.48* mdr
363266 Agfg1 1 0 NA 0.14 0.07 NA 0.24 0.16 dr
364403 Blk 1 0 NA – 0.08 0.21 NA – 0.15 0.13
500636 Rnf144a 1 0 NA – 0.21 – 0.05 NA 0.36* 0.11
56822 Cd86 1 0 – 0.04 0.02 0.02 – 0.09 0.02 0.32* d
58947 Hgfac 1 0 NA 0.57* 0.81* NA 1.31* 1.67*
65158 Rab2a 1 0 0.16 – 0.02 0.00 0.16 0.08 0.24* dc
691504 Zfpm1 1 0 0.17 – 0.25 – 0.13 0.16 0.00 – 0.47* mdr
25638 Pde4a 0 1 – 0.06 – 0.03 0.13 0.08 0.01 – 0.21
290666 Sugp1 0 1 0.00 0.10 – 0.11 0.08 0.33* 0.14
290668 Mau2 0 1 0.03 0.00 – 0.02 0.08 0.03 0.05
293652 Ndufs8 0 1 0.04 – 0.13 – 0.29* – 0.05 0.09 – 0.15*
302495 Rap2c 0 1 NA 0.12 0.15 NA 0.17 0.37*
361653 Armc5 0 1 – 0.11 0.00 – 0.15 0.11 0.29* 0.21*
361809 Zfp523 0 1 0.07 0.12 0.17* 0.09 0.11 – 0.01
362339 Creb3l2 0 1 NA 0.09 0.23* NA 0.14 – 0.06
64565 Tmprss11d 0 1 – 0.15 0.06 – 0.19 0.09 0.16 – 0.01
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Validation by whole‑proteome mass spectrometry
LC–MS was used to assess hepatic protein abundance from 
L–E and H/W rats, treated with either 100 μg/kg TCDD or 
control for 4 days (n = 5 animals per group). As wasting syn-
drome is a well-documented outcome in L–E rats (Linden 
et al. 2014), an additional control group of feed restricted, 
vehicle treated L–E rats (FRC) were used to remove non-
TCDD mediated changes to protein abundance. LC–MS 
provided abundance estimates for a total of 1719 unique pro-
teins. We identified 49 proteins with significantly different 
abundance (|log2 fold change| > 1, padj < 0.05) between H/W 
and L–E treated with vehicle alone (Fig. 5a, basal). A further 
22 proteins exhibited differential abundance between feed-
restricted and control L–E rat liver (Fig. 5a, FRC). Further-
more, 26 and 113 proteins demonstrated statistically signifi-
cant differences in abundance in H/W (TCDD vs. vehicle) 
and L–E (TCDD vs. FRC) respectively, of which 20 were 
similarly altered in both groups (Fig. 5a, H/W and L–E). This 
overlap included multiple members of the “AHR-core” gene 
battery: CYP1A1, CYP1A2, CYP1B1, CYP2A1, NQO1 
and ALDH3A1. No single gene was changed in all four 
groups, but abundance of CYP2C70 was reduced by TCDD 
in both strains  (log2 fold change = − 2.5, padj = 6.78 × 10−17 
in L–E and  log2 fold change = − 0.99, padj = 3.52 × 10−4 
in H/W), showed significantly higher basal abundance in 
H/W  (log2 fold change = 1.08, padj = 7.14 × 10−5) but was 
not affected by feed restriction  (log2 fold change = 0.7, 
padj = 1.37 × 10−3). We compared differential abundance of 
RNA and protein (n = 1230 genes with both data types) for 
each rat strain and found these were poorly correlated overall 
(Fig. 5b, c) but were well-correlated when focusing on those 
genes with significant TCDD-associated RNA changes in 
either strain (Pearson’s r = 0.47, p = 3.8 × 10−3 for H/W; 
r = 0.24, p = 2.6 × 10−3 for L–E).
We next examined abundance patterns for those genes 
with significant differences in the TCDD-sensitive L–E 
rat liver at both the RNA and protein level, 4 days fol-
lowing exposure to TCDD (n = 21, (|log2 fold change| > 1, 
padj < 0.05). We found increased abundance of Igtp (inter-
feron gamma induced GTPase) and Impa2 (inositol 
monophosphatase 2) for both RNA and protein that was 
not observed in H/W. Interestingly, Igtp demonstrated mul-
tiple high-impact homozygous variants within the H/W 
genome that may contribute to this lack of change at the 
RNA and protein levels. Seven genes demonstrated sig-
nificantly reduced RNA and protein abundance following 
TCDD exposure in L–E rats but not H/W rats. Five of these 
(Kmo, Slc27a5, Slco1a1, Cyp2e1 and Cyp2j3) with mouse 
orthologues showed significant (|log2 fold change| > 1, 
padj < 0.05) or near significant (|log2 fold change > 0.5|, 
padj < 0.05) reduced transcript abundance in both DEL and 
rWT ratonized mice (500 μg/kg TCDD, 4 days).
Four genes exhibited significantly reduced protein 
abundance in H/W rat liver alone. These included SNRK, 
whose expression was significantly decreased at the protein 
 (log2 fold change = -13.6, padj = 3.8 × 10−5) but not RNA 
 (log2 fold change = − 0.03) levels following TCDD expo-
sure. Fasn demonstrated reduced abundance of both RNA 
 (log2 fold change = − 1.13, padj = 0.036) and protein  (log2 
fold change = − 0.97, padj = 1.0 × 10−8) in H/W but it also 
showed reduced transcript abundance in many TCDD-sen-
sitive mouse models (DEL, rWT, C57BL/6). When looking 
at proteins with increased abundance unique to H/W (n = 4), 
three had measurements for transcript abundance but none 
of these were statistically significant and they often showed 
Fig. 5  Integrated comparison of − omics data in rat liver. a Overlap 
of proteins (unique gene IDs) with statistically significantly different 
protein abundance: basal = H/W (vehicle treated) vs. L–E (vehicle 
treated); FRC = L–E (feed-restricted, vehicle treated) vs. L–E (vehicle 
treated); H/W = TCDD vs. vehicle; L–E = TCDD vs. feed-restricted, 
vehicle treated. Correlation of RNA and protein differential abun-
dance (M TCDD relative to control) in liver from b H/W and c L–E 
rats; red points show position of “AHR-core” genes, with select genes 
labeled. Pearson’s correlations (R) and p values are shown
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changes in the opposite direction. This pattern of non-sig-
nificant, yet often reduced, abundance was also observed in 
our mouse models.
Finally, we sought to examine protein abundance for those 
genes having phenotype-associated transcriptomic changes 
(as described in above sections), however none were confi-
dently detected via mass-spectrometry. Differential protein 
abundance was also not observed amongst genes with high 
impact sequence variants. Amongst genes with high impact 
sequence variants, differential abundance of CYP1B1 was 
not strain specific, while IGTP showed altered (increased) 
abundance of both RNA and protein in only L–E rats and 
RYR1 showed increased protein abundance, also in L–E rats. 
Interestingly, Igtp also showed a loss of the AHRE-2 bind-
ing motif in L–E rats, with no changes detected in H/W rats. 
Having altered AHRE-1 (full) binding sites did not result 
in any detectable differences in protein abundance between 
strains, however there was an additional AHRE-1 (extended) 
motif adjacent to Snrk in H/W that may contribute to its 
decreased abundance.
Discussion
There is abundant evidence that the AHR structure is a 
primary determinant of susceptibility to TCDD toxic-
ity (Fernandez-Salguero et al. 1996; Schmidt et al. 1996; 
Mimura et al. 1997; Tijet et al. 2006; Moffat et al. 2007; 
Boutros et al. 2009; reviewed in Pohjanvirta et al. 2011). 
Two rodent species, mice and rats, show inter-strain dif-
ferences in response to TCDD-insult depending on AHR 
genotype (Chang et al. 1993; Boutros et al. 2011; Yao et al. 
2012). Furthermore, previous studies have shown little over-
lap in the transcriptomic response following TCDD expo-
sure in TCDD-sensitive strains of mouse vs. rat (Boverhof 
et al. 2006; Boutros et al. 2008). These differences may in 
part be due to the intrinsic genetic variation between model 
organisms. In order to remove this confounding factor, we 
examined transgenic mouse models harbouring different rat 
AHR isoforms within an identical genetic background. To 
further support this analysis, we performed whole-genome 
sequencing of two common rat models with highly different 
responses to TCDD exposure, due to bearing the variant 
AHR isoforms utilized in our transgenic models. By con-
trasting the profiles of homozygous SNVs in each strain with 
the transcriptional landscape of various rat and mouse mod-
els, we aim to identify phenotype-pertinent genes.
Previous studies contrasting basal transcriptomic pro-
files of mice and rats with different AHR genotypes (Tijet 
et al. 2006; Sun et al. 2014) identified large differences in 
mRNA abundance of many genes in the absence of xenobi-
otic AHR ligands. Contrary to this, there was little difference 
among basal transcriptomic profiles among our transgenic 
mice, suggesting that these variations in AHR structure have 
little effect on basal gene expression. This may be partly 
explained by differences in the mRNA abundance of Ahr 
itself—in liver tissue, basal expression of TCDD-sensitive 
Ahr isoforms (rWT, DEL) is considerably higher than for 
the TCDD-resistant INS isoform in these transgenic mice 
(Pohjanvirta 2009). This represents an intriguing pattern and 
will require further study to better understand the inherent 
differences in activity of these isoforms.
The AHR alone is sufficient to explain much of the 
observed variation in sensitivity to TCDD: at all doses 
assessed, ~ 50% of genes demonstrating TCDD-mediated 
changes in transcription were unique to a single transgenic 
model. For example, at the highest dose studied (1000 μg/
kg TCDD), 33.8%, 11.7%, 5.2%, and 0.3% of differen-
tially abundant transcripts were specific to the rWT, DEL, 
C57BL/6 and INS cohorts respectively (of a total 3076 with 
altered mRNA abundance). These proportions were fairly 
consistent across doses, with the proportion of genes with 
altered mRNA abundance that were unique to C57BL/6 
negatively correlated with dose, while INS showed a posi-
tive correlation; DEL and rWT were less consistent, with 
each showing ~ 30% unique changes at 500 or 1000 μg/kg 
TCDD, respectively. At first glance, it seems unusual that 
a considerable transcriptomic response was detected in the 
transgenic model expressing the TCDD-semi-resistant H/W 
DEL isoform. Both the DEL and INS isoforms are expressed 
naturally in the H/W rat, in roughly 15–85% proportions; 
however, the DEL isoform displays a significantly higher 
intrinsic transactivation activity (Moffat et al. 2007), par-
tially explaining the reduced resistance observed in these 
models (Pohjanvirta 2009). Since our ratonized mice varied 
only at the AHR locus, the remaining 50% of differentially 
transcribed genes may be due to additional transcription 
factors as either primary or secondary effects, as suggested 
by the low overlap between early (EXP1) and late (EXP2) 
studies.
We identified twelve candidates for the hypothesized 
TCDD-resistance associated gene “B”. These genes dem-
onstrate altered TFBS within their promoter regions and 
altered transcript abundance in rats, but not the correspond-
ing AHR-ratonized mice. Here we focused on the AHRE-1 
(full) motif, because it results in the most productive 
receptor-DNA interaction (Lusska et al. 1993). In particu-
lar, three genes were identified that had lost this motif in 
H/W rats, and demonstrated altered mRNA abundance in 
only L–E (Sugp1, Rap2c and Armc5). SURP and G patch 
domain containing 1 (Sugp1) encodes a splicing factor that 
had increased mRNA abundance in TCDD-exposed L–E 
rat liver (4 days); however, the magnitude of change was 
small  (log2 fold change = 0.33). Rap2c is member of RAS 
oncogene family that showed increased mRNA abundance 
in TCDD-exposed L–E rat liver (10 days), again however, 
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the magnitude of change was small  (log2 fold change = 0.37). 
Armadillo repeat containing 5 (Armc5), showed signifi-
cantly increased mRNA abundance following treatment 
in L–E rat liver, as well as in liver of mice expressing the 
rWT-Ahr, while it was repressed in livers of C57BL/6 mice 
(despite also containing a proximal AHRE-1 (full) motif). 
Little is known about this gene; however, it is a putative 
tumour suppressor gene (Assie et al. 2013).
Genomic sequencing further revealed loss of one of two 
AHRE-1 (full) occurrences from the promoter region of 
the CXXC finger protein 5 (Cxxc5) in the H/W rat along 
with significantly repressed mRNA abundance in livers of 
TCDD-sensitive L–E (4 days:  log2 fold change = − 0.31, 
padj = 8.8  ×  10−3 and 10  days:  log2 fold change = −  1, 
padj = 3.1 × 10−6) and Ln-C (19 h,  log2 fold change = − 0.45, 
padj = 0.014) rats. Of interest, the transcription factor CXXC5 
has been shown to inhibit expression of cytochrome c 
oxidase by binding to an oxygen response element in the 
proximal promoter of Cox4l2 in human lung cells (Aras 
et al. 2013). The delayed onset of repression of Cxxc5 in 
TCDD-sensitive cohorts may be a secondary response due 
to the presence of oxidative stress, and possibly corresponds 
with altered energy metabolism observed in these animals. 
Another gene, Mafb (v-maf musculoaponeurotic fibrosar-
coma oncogene family, protein B), has a single AHRE-1 
(full) motif in H/W rats but two in L–E rats and exhibited 
significantly repressed mRNA abundance in L–E rats. This 
may bear on the disparate developmental toxicity outcomes 
upon TCDD exposure observed in these strains: cleft palate 
was not seen at any dose in H/W rat progeny but it occurred 
in 71.4% of offspring in L–E rats treated with 5 µg/kg 
TCDD (Huuskonen et al. 1994). In humans, Mafb variants 
have been associated with cleft palate and lip (Zhang et al. 
2018). Finally, a novel AHRE-1 (full) motif was detected 
in the promoter region of Hgfac (HGF activator) in H/W 
rats that was absent in L–E rats. mRNA abundance for this 
gene was significantly increased in TCDD-exposed liver 
from L–E rats (4 and 10 days,  log2 fold change = 1.3 and 
1.7, padj = 1.16 × 10−12 and 1.16 × 10−17) with a more muted 
response in H/W rats (4 and 10 days,  log2 fold change = 0.57 
and 0.81, padj = 3.7 × 10−4 and 4.28 × 10−8). These genes 
provide interesting candidates for gene “B” that require fur-
ther studies into its potential involvement in the onset of 
TCDD-toxicities.
In H/W rats, the proteomics data revealed a high cor-
relation with transcriptomic findings when genes with sig-
nificant TCDD-associated RNA changes were considered 
(r = 0.47, p = 3.8 × 10−3); in L–E rats the correlation was 
less striking. Our combined liver proteomic and transcrip-
tomic analyses also brought to light several candidate pro-
teins to underlie the strain sensitivity differences in TCDD 
toxicity. These included Igtp, Impa2 and Snrk. In all of these 
cases, parallel changes were recorded at both mRNA and 
protein levels. Thus, the roles of their genes in TCDD toxic-
ity should be studied further in the future.
The purpose of this study was to ascertain the mecha-
nism of classic TCDD toxicity using various model systems, 
including transgenic mice to compare various rat Ahr vari-
ants in a system with a homogeneous genetic background, 
and various strains of rat, each with differing phenotypic 
responses to TCDD. To accomplish this, we generated 
unique proteomic, transcriptomic and genomic datasets 
that provide multiple levels of evidence. Using this valuable 
resource, we identified several genes whose transcription 
was selectively altered by TCDD in either TCDD-sensitive 
or TCDD-resistant cohorts, a differential response that can 
be attributed to the particular AHR isoform expressed in 
each cohort. Pxdc1 in particular demonstrated differential 
transcription between TCDD-sensitive and TCDD-resistant 
models across both mice and rats. However, the transcrip-
tional responsiveness of this gene could not be explained by 
genomic differences in AHR-binding sites, as the transcrip-
tion factor binding site analysis revealed highly variant sites 
between species, and no major difference between strains of 
rat. Our genomic sequence analysis allowed identification of 
differences between sensitive and resistant rat strains, which 
are potential “gene B” candidates. For instance, Cxxc5 har-
boured fewer occurrences of AHRE-1 (full) TFBSs in H/W 
relative to L–E, and had reduced RNA abundance in sensi-
tive strains/lines. This is therefore a promising candidate for 
further study in relation to mechanisms of TCDD toxicity 
and regulatory roles of the AHR.
Materials and methods
Animal handling
Three separate experiments were performed (Fig. 1). In the 
first, adult male C57BL/6Kuo, rWT and DBA/2 J mice were 
evaluated. In the second, adult male C57BL/6 mice carry-
ing 4 different Ahr isoforms were examined: C57BL/6Kuo 
and rWT, DEL, and INS transgenic mice. Transgenic mice 
were generated as described previously (Pohjanvirta 2009). 
Briefly, animals were bred from Ahr-null mice to avoid inter-
ference by the C57BL/6 AHR. Once established, transgenic 
colonies were bred at the National Public Health Institute, 
Division of Environmental Health in Kuopio, Finland. For 
this study, animal ages varied from 12 to 23 weeks. All 
animals were housed singly in Makrolon cages. The hous-
ing environment was maintained at 21 ± 1 °C with relative 
humidity at 50 ± 10%, and followed a 12-h light cycle. Tap 
water and R36 pellet feed (Lactamin, Stockholm, Sweden) 
or Altromin 1314 pellet feed (DBA/2 mice; Altromin Spe-
zialfutter GmbH & Co. KG, Lage, Germany) were available 
ad libitum.
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In the first experiment (EXP1), a total of 36 mice were 
used (n = 12 per genotype), divided into groups of four mice 
per treatment group. Mice were treated by oral gavage with a 
single dose of 0, 5, or 500 μg/kg TCDD dissolved in corn oil 
vehicle (Supplementary Table 1). Animals were euthanized 
by carbon dioxide, followed immediately by cardiac exsan-
guination 19 h following treatment. In the second experi-
ment (EXP2), a total of 84 mice were used, divided into 
groups according to Ahr isoform. Mice were treated by oral 
gavage with a single dose of 0, 125, 250, 500, or 1000 μg/
kg TCDD dissolved in corn oil vehicle (Supplementary 
Table 1). Animals were euthanized by cervical dislocation 
4 days following exposure and their livers excised. A single 
rWT animal from the 1000 μg/kg TCDD group died prema-
turely and was thus excluded from the study, thereby leaving 
83 animals.
Microarray hybridization
Mouse livers were frozen in liquid nitrogen immediately 
upon excision and stored at − 80 °C. Tissue samples were 
homogenized and RNA was isolated using an RNeasy Mini 
Kit (Qiagen, Mississauga, Canada) according to the manu-
facturer’s instructions. Total RNA was quantitated using a 
NanoDrop UV spectrophotometer (Thermo Scientific, Mis-
sissauga, ON) and RNA quality was verified using RNA 
6000 Nano kits on an Agilent 2100 Bioanalyzer (Agilent 
Technologies, Mississauga, ON). RNA abundance levels 
were assayed using Affymetrix Mouse Gene 1.1 ST arrays 
(Affymetrix Mouse Gene 2.0 ST arrays were used for the 
C57BL/6 mice for EXP1) at The Centre for Applied Genom-
ics (TCAG; Toronto, ON) as described previously (Boutros 
et al. 2011).
Data pre‑processing and statistical analysis
Raw data (CEL files) were loaded into the R statistical envi-
ronment (v3.4.3) using the affy package (v1.48.0) (Gautier 
et al. 2004) of the BioConductor library (Gentleman et al. 
2004) and pre-processed using the RMA algorithm (Irizarry 
et al. 2003). Each group (experiment/AHR isoform) was pre-
processed independently to avoid masking any differences 
between isoforms. Probes were mapped to EntrezGene IDs 
using the custom mogene11stmmentrezgcdf and mogen-
e20stmmentrezgcdf packages (v22.0.0) (Dai et al. 2005). 
Visual inspection of array distribution and homogeneity of 
the results suggested the presence of outliers. These were 
further identified using Dixon’s Q test (Dixon 1950) as 
implemented in the outliers package (v0.14) in R, which 
was used to compare abundance patterns of “AHR-core” 
genes for each genotype/treatment combination (Supple-
mentary Figure 1). Three TCDD-treated rWT animals were 
removed from EXP2, along with one control DBA animal 
and one TCDD-treated rWT animal from EXP1, as mRNA 
abundance for these AHR-core genes closely resembled the 
control animals (FDR-adjusted Dixon’s Q test, p < 0.05 for 2 
or more AHR-core genes, requiring at least one of Cyp1a1, 
Cyp1a2 or Cyp1b1; Supplementary Figure 1). Remaining 
arrays were re-processed without outliers (Supplementary 
Figures 2 and 3). ComBat was run on the combined data-
set, using the sva package (v3.24.4) for R, to adjust RMA 
normalized values for comparison across batches (Supple-
mentary Fig. 4). General linear modeling was performed to 
determine which genes were significantly altered following 
exposure to TCDD. Specifically, for each gene (i) the abun-
dance (Y) was modelled as Yi = β0 + β1X, where X indicates 
the dose of TCDD administered. Each experiment/AHR iso-
form was modelled independently, using RMA normalized 
values (without ComBat correction as each group was pro-
cessed as a single batch) with each dose treated as a factor. 
Genes were modelled as a univariate combination of a basal 
effect (β0) (represented by the vehicle control) and TCDD 
effect (β1) with contrasts fit to compare each dose–effect to 
baseline. Standard errors of the coefficients were smoothed 
using an empirical Bayes method (Smyth 2004) and signifi-
cance was identified using model-based t-tests, followed by 
FDR adjustment for multiple testing (Storey and Tibshirani 
2003). Sensitivity of results to various  padj-value cut-offs 
was assessed (Fig. 2b, Supplementary Figure 4c–i). Those 
genes deemed significantly altered (padj < 0.05 and |coef-
ficient| > 1) following treatment were examined in down-
stream analyses. All statistical analyses were performed 
using the limma package for R (v3.32.10) (Smyth 2004). 
Venn diagrams were created using the VennDiagram pack-
age (v1.6.21) for R (Chen and Boutros 2011) to visualize 
overlap between groups. All other data visualizations were 
generated using the BPG plotting package (v5.9.8) (P’ng 
et al. 2017), using the lattice (v0.20-38) and latticeExtra 
(v0.6-28) packages for R.
Rat‑mouse overlap of differentially abundant RNAs
Publicly available data for male H/W and L–E rats, as well 
as two lines (Ln-A and Ln-C) derived from L–E × H/W 
crosses, were used for comparison (Moffat et  al. 2010; 
Boutros et al. 2011; Yao et al. 2012; Prokopec et al. 2017). 
Data consisted of the hepatic transcriptomic responses of 
rats to a single dose of TCDD (100 μg/kg in corn oil) at three 
time points (19 h, 4 and 10 days). Notably, in the 4 day expo-
sure group, L–E rats treated with TCDD were contrasted 
with feed-restricted, vehicle treated controls (FRC). All data 
were available from the TCDD.Transcriptomics (v2.2.5) 
package (Prokopec et al. 2017) for R. Due to the use of dif-
ferent microarrays between studies, HomoloGene (build 68) 
was used to identify orthologous genes. Homologene IDs 
which mapped to multiple EntrezGeneIDs were discarded. 
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In total, 11,932 genes were found to be orthologous between 
species and were used for overlap analyses (Supplementary 
Table 6).
Pathway analysis
Pathway analysis was conducted in order to elucidate the 
functions of genes demonstrating significantly altered 
mRNA abundance for each AHR isoform cohort. Analysis 
was performed using the High-Throughput GoMiner web 
interface (application build 469, database build 2011-01, 
accessed 2019-02) (Zeeberg et al. 2005). A separate run was 
performed for each mouse AHR isoform and each available 
rat dataset. We compared significantly altered genes against 
a randomly drawn sample from all orthologous mouse (or 
rat) genes in the dataset, using an FDR threshold of 0.1, 
1000 randomizations, all mouse (or rat) databases and look-
up options, and all GO evidence codes and ontologies (Sup-
plementary Table 4). Results were further filtered using a 
threshold of padj < 0.01 and an enrichment score > 15 in at 
least one of the examined groups. This resulted in 29 unique 
gene ontologies to examine further.
Genome sequencing
Untreated adult male outbred H/W (Kuopio) and inbred 
L–E (Turku/AB) (Pohjanvirta and Tuomisto 1990) rats 
were euthanized by decapitation and their livers excised. 
Tissue was frozen in liquid nitrogen and shipped to the ana-
lytic facility on dry ice. Genomic DNA (gDNA) was iso-
lated and whole genome sequencing performed by Genome 
Technologies at the Ontario Institute for Cancer Research 
and Applied Biosystems (Burlington, ON) using the AB 
SOLiD platform using mate-pair and fragment libraries. For 
mate-pair libraries, 100 µg of gDNA was sheared to 1-2 kb 
fragments using the GeneMachine HydroShear standard 
shearing assembly and 1.5 kb fragments isolated using 1% 
agarose gel size selection. Mate-pair libraries were circular-
ized and constructed according to standard SOLiD Long 
Mate-Pair library protocols (Applied Biosystems, Burling-
ton, ON). Following library quantitation via TaqMan qPCR 
(Applied Biosystems, Burlington, ON), libraries underwent 
emulsion PCR and bead enrichment according to standard 
SOLiD protocols (Applied Biosystems, Burlington, ON). 
Enriched libraries were then sequenced 2 × 50 bp using 
SOLiD 3 sequencing chemistry (Applied Biosystems, Burl-
ington, ON). A similar procedure was used to produce frag-
ment libraries, with the following changes: 1 µg of gDNA 
was sheared to 70-90 bp fragments using the Covaris S220 
(Covaris Inc., Woburn, MA) and 150 bp fragment libraries 
were constructed according to standard SOLiD Fragment 
library protocols (Applied Biosystems, Burlington, ON). 
Libraries were quantified and enriched as described above 
and sequenced 1x50 bp using SOLiD 3 sequencing chemis-
try (Applied Biosystems, Burlington, ON).
Sequence alignment and variant calling
Raw reads were split into manageable chunks 
(n = 10,000,000 reads) and aligned to the rat reference 
genome (rn6) using BFAST (v0.7.0a) with default param-
eters. Resulting SAM format files were converted to BAM 
format and coordinate sorted, followed by mark duplicates, 
merging of partial files and indexing using Picard (v1.92). 
Indel realignment/recalibration were performed using GATK 
(v3.7.0), followed by variant detection using GATK’s Hap-
lotypeCaller, with known variants identified using dbSNP 
(build 149, downloaded from UCSC on 2018-11-19). 
Resulting variants were filtered such that any variants with a 
depth < 6 reads and SNPs common to previously sequenced 
rat strains (Atanur et al. 2013) were excluded [GATKs Lifto-
verVariants; using rn4 to rn6 chain file from UCSC, and 
vcftools (v0.1.15)]. Variant annotation was performed using 
SnpEff (v4.3t) with the rn6 database (Rnor_6.0.86). As these 
are highly controlled strains, only homozygous variants were 
carried forward for analysis. This reduced the number of 
variants by 95% to 176,578 for H/W and by 92% to 161,620 
for L–E.
Transcription factor binding site analyses
The modified rat genomes (H/W and L–E) were used to 
identify differing transcription factor binding sites (TFBS) 
between strains. Conservation scores, REFLINK and REF-
FLAT tables for rn6 were downloaded from the UCSC 
genome browser on August 09, 2018 (Karolchik et al. 2003). 
For each rat strain examined (H/W and L–E), the unique 
variants identified above were inserted into the reference 
genome (rn6) FASTA file. For each rat strain, as well as 
for mouse (mm9), the genome was searched for the follow-
ing motifs: AHRE-I (core) GCGTG (Denison et al. 1988), 
AHRE-I (extended) T/NGCGTG (Swanson et al. 1995), 
AHRE-I (full) [T|G]NGCGTG[A|C][G|C]A (Lusska et al. 
1993) and AHRE-II CATG(N6)C[T|A]TG (Sogawa et al. 
2004) and ARE TGAC(N3)GC (Rushmore et al. 1991). 
Exposed motifs were annotated to specific genes if they 
occurred within a promoter region (± 3 kbp of the transcrip-
tion start site) and a PhyloHMM conservation score from 0 
(weak conservation) to 1 (strong conservation) was calcu-
lated (Supplementary Table 2).
Sample preparation and proteolytic digestion 
of proteins
Adult male H/W and L–E rats were treated, and tissue 
collected as described previously (Linden et  al. 2014). 
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Proteomics analyses were carried out at the Meilahti Clini-
cal & Basic Proteomics Core Facility of the University of 
Helsinki. Liver pieces were homogenized in 7 M urea, 2 M 
thiourea, 4% CHAPS using  Percellys® 24 homogenizer (Ber-
tin Technologies). For each sample, 10 µg of total protein 
lysate was processed for digestion, using a modified FASP 
protocol (Wisniewski et al. 2009; Scifo et al. 2015). In brief, 
the lysate buffer was exchanged by washing it several times 
with 8 M urea, 0.1 M Tris, pH 8 (Urea buffer, UB). The 
proteins were reduced by addition of 10 mM DTT in UB 
and alkylated with 50 mM iodoacetamide in UB, after wash-
ing out the DTT-containing solution. 1:50 w/w of Lysine-C 
endopeptidase (Wako) was added to ~ 4 M urea/0.1 M Tris 
pH 8 and incubated at room temperature overnight. The 
peptide digests were collected by centrifugation and trypsin 
solution was added in a ratio of 1:50 w/w in 50 mM ammo-
nium bicarbonate. As before, the digests were collected and 
combined. The peptide samples were cleaned using C18-
reverse phase ZipTip™ (Millipore), resuspended in 1%TFA 
and sonicated in water bath for 1 min.
LC‑HDMSe
300 ng of digested proteins/replicate (3 replicate runs per 
sample) was injected for LC–MS analysis. The peptides 
were separated by nanoAcquity UPLC system (Waters) 
equipped with a trapping column 5 μm Symmetry C18 
180 μm × 20 mm C18 reverse phase (Waters), followed by an 
analytical 1.7 µm, 75 µm × 250 mm BEH-130 C18 reversed-
phase column (Waters), in a single pump trapping mode. 
The injected sample analytes were trapped at a flow rate of 
15 µl/min in 99.5% of solution A (0.1% formic acid). After 
trapping, the peptides were separated with a linear gradi-
ent of 3–35% of solution B (0.1% formic acid/acetonitrile), 
for 100 min at a flow rate 0.3 µl/min and stable column 
temperature of 35 °C. Every sample run was succeeded by 
two empty runs to wash out any remaining peptides from 
previous runs. Samples were run in ion mobility assisted 
data-independent analysis mode  (HDMSE), in a Synapt 
G2-S mass spectrometer (Waters), by alternating between 
low collision energy (6 V) and high collision energy ramp 
in the transfer compartment (20–45 V) and using 1 s cycle 
time. The separated peptides were detected online with 
mass spectrometer, operated in positive, resolution mode 
in the range of m/z 50-2000 amu. 150 fmol/µl of human 
 [Glu1]-fibrinopeptide B (Sigma) in 50% acetonitrile/0.1% 
formic acid solution at a flow rate of 0.3 µl/min was used for 
a lock mass correction, applied every 30 s.
Database mining of LC‑HDMSE
Relative quantification between samples using precur-
sor ion intensities was performed with Progenesis QI for 
Proteomics™ Informatics for Proteomics software (Non-
linear Dynamics, Waters) and ProteinLynx Global Server 
(PLGS V3.0).  MSe parameters were set as follows: low 
energy threshold of 135 counts, elevated energy threshold 
of 30 counts, and intensity threshold of precursor/fragment 
ion cluster 750 counts. Chromatograms were automatically 
aligned by the Progenesis QI for Proteomics™ software 
using the default values by following the wizard, and those 
that had alignment score ≥ 70% to the reference run were 
selected for further analysis. To compare the control(s) 
to other subjects we utilized the between-subject design 
scheme of Progenesis QI for Proteomics™ software. The 
ANOVA calculation applied by this scheme assumes that 
the conditions are independent and applies the statistical test 
which presumes the means of the conditions are equal.
Database searches were carried out against Rattus nor-
vegicus UniProtKB-SwissProt, reviewed, database (release 
2019_5, 8062 entries) with Ion Accounting algorithm and 
using the following parameters: peptide and fragment tol-
erance: automatic, maximum protein mass: 500 kDa, min 
fragment ions matches per protein ≥ 7, min fragment ions 
matches per peptide ≥ 3, min peptide matches per pro-
tein ≥ 1, primary digest reagent: trypsin, missed cleavages 
allowed: 2, fixed modification: carbamidomethylation C, 
variable modifications: deamidation of NQ residues, oxida-
tion of Methionine and false discovery rate (FDR) < 4%. All 
identifications were subsequently refined to Rattus norvegi-
cus only identifiers and the protein lists simplified by protein 
grouping. Protein quantitation was performed entirely on 
non-conflicting proteins identifications, using precursor ion 
intensity data and standardized expression profiles. Addi-
tional filters in Progenesis QI for Proteomics™ applied to 
final data increased the stringency of accepted protein leads 
by limiting the ratio between treated as compared to controls 
(fold change > 2 in either direction of up- or down-regula-
tion, computed from averaged, normalized protein intensi-
ties, and p < 0.05 by ANOVA for all comparisons).
Statistical analysis of proteomic data
Following above filtering, normalized protein intensities 
were provided for 1734 unique protein/protein groups. 
Additional filtering was applied to remove proteins with low 
confidence score (< 10), leading to removal of 15 proteins. 
Cases with a normalized intensity of 0 were replaced with 
the minimum, non-zero intensity present in the dataset. Data 
were then  log2-transformed and linear modeling applied, 
with technical replicates treated as a random effect using 
the limma package for R (v3.32.10) (Smyth 2004). Contrasts 
were fit to compare each dose–effect to baseline (TCDD 
vs. vehicle alone for H/W; TCDD vs. vehicle treated, feed-
restricted controls for L–E), as well as identify basal differ-
ences between strains. Standard errors of the coefficients 
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were smoothed using an empirical Bayes method (Smyth 
2004) and significance was identified using model-based 
t-tests, followed by FDR adjustment for multiple testing 
(Storey and Tibshirani 2003). Model results are available in 
Supplementary Table 7.
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